July 29, 2014 / 5:11 AM / 3 years ago

Roche says Gazyvaro approved in Europe against leukemia

ZURICH, July 29 (Reuters) - Roche said on Tuesday that European regulators approved its drug Gazyvaro, or obinutuzumab, for patients with chronic lymphocytic leukaemia, boosting the Swiss group's line-up of new cancer treatments.

The new medicine is an improved follow-on medicine to the Swiss drugmaker's $7 billion-a-year Rituxan, or MabThera, and Roche is hoping to switch as many patients as possible to the newer product before Rituxan faces competition from cheaper copies.

The move endorses a favorable recommendation in May from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP), which are normally followed by the European Commission. (Reporting By Katharina Bart)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below